Diabetic Peripheral Neuropathy: Diagnosis and Treatment

Johan       Røikjer; Carsten    Dahl    Mørch; Niels       Ejskjaer
doi:10.2174/1574886315666200731173113
Abstract

Background: Diabetic peripheral neuropathy (DPN) is traditionally divided into large and small fibre neuropathy (SFN). Damage to the large fibres can be detected using nerve conduction studies (NCS) and often results in a significant reduction in sensitivity and loss of protective sensation, while damage to the small fibres is hard to reliably detect and can be either asymptomatic, associated with insensitivity to noxious stimuli, or often manifests itself as intractable neuropathic pain.
Objective: To describe the recent advances in both detection, grading, and treatment of DPN as well as the accompanying neuropathic pain.
Methods: A review of relevant, peer-reviewed, English literature from MEDLINE, EMBASE and Cochrane Library between January 1st 1967 and January 1st 2020 was used.
Results: We identified more than three hundred studies on methods for detecting and grading DPN, and more than eighty randomised-controlled trials for treating painful diabetic neuropathy.
Conclusion: NCS remains the method of choice for detecting LFN in people with diabetes, while a gold standard for the detection of SFN is yet to be internationally accepted. In the recent years, several methods with huge potential for detecting and grading this condition have become available including skin biopsies and corneal confocal microscopy, which in the future could represent reliable endpoints for clinical studies. While several newer methods for detecting SFN have been developed, no new drugs have been accepted for treating neuropathic pain in people with diabetes. Tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors and anticonvulsants remain first line treatment, while newer agents targeting the proposed pathophysiology of DPN are being developed.
Keywords: Peripheral, neuropathy, diagnosis, treatment, diabetic, confocal microscopy.
« Previous Next »
[1] 
Vinik AI, Nevoret ML, Casellini C, Parson H. Diabetic neuropathy. Endocrinol Metab Clin North Am  2013; 42(4): 747-87.
[http://dx.doi.org/10.1016/j.ecl.2013.06.001] [PMID: 24286949] 
[2] 
Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr Diab Rep  2019; 19(10): 86.
[http://dx.doi.org/10.1007/s11892-019-1212-8] [PMID: 31456118] 
[3] 
Divisova S, Vlckova E, Hnojcikova M, et al. Prediabetes/early diabetes-associated neuropathy predominantly involves sensory small fibres. J Peripher Nerv Syst  2012; 17(3): 341-50.
[http://dx.doi.org/10.1111/j.1529-8027.2012.00420.x] [PMID: 22971096] 
[4] 
Løseth S, Stålberg E, Jorde R, Mellgren SI. Early diabetic neuropathy: thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies. J Neurol  2008; 255(8): 1197-202.
[http://dx.doi.org/10.1007/s00415-008-0872-0] [PMID: 18574618] 
[5] 
Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology  2001; 57(9): 1701-4.
[http://dx.doi.org/10.1212/WNL.57.9.1701] [PMID: 11706115] 
[6] 
Breiner A, Lovblom LE, Perkins BA, Bril V. Does the prevailing hypothesis that small-fiber dysfunction precedes large-fiber dysfunction apply to type 1 diabetic patients? Diabetes Care  2014; 37(5): 1418-24.
[http://dx.doi.org/10.2337/dc13-2005] [PMID: 24574353] 
[7] 
Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes  1997; 46(Suppl. 2): S54-7.
[http://dx.doi.org/10.2337/diab.46.2.S54] [PMID: 9285500] 
[8] 
Umapathi T, Tan WL, Loke SC, Soon PC, Tavintharan S, Chan YH. Intraepidermal nerve fiber density as a marker of early diabetic neuropathy. Muscle Nerve  2007; 35(5): 591-8.
[http://dx.doi.org/10.1002/mus.20732] [PMID: 17221881] 
[9] 
Tesfaye S, Vileikyte L, Rayman G, et al. Toronto Expert Panel on Diabetic Neuropathy. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev  2011; 27(7): 629-38.
[http://dx.doi.org/10.1002/dmrr.1225] [PMID: 21695762] 
[10] 
Tesfaye S, Boulton AJM, Dyck PJ, et al. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care  2010; 33(10): 2285-93.
[http://dx.doi.org/10.2337/dc10-1303] [PMID: 20876709] 
[11] 
Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American diabetes association. Diabetes Care  2017; 40(1): 136-54.
[http://dx.doi.org/10.2337/dc16-2042] [PMID: 27999003] 
[12] 
Brock C, Hansen CS, Karmisholt J, et al. Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy. Br J Clin Pharmacol  2019; 85(11): 2512-23.
[http://dx.doi.org/10.1111/bcp.14063] [PMID: 31338868] 
[13] 
Kennedy WR, Navarro X, Goetz FC, Sutherland DER, Najarian JS. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med  1990; 322(15): 1031-7.
[http://dx.doi.org/10.1056/NEJM199004123221503] [PMID: 2320063] 
[14] 
Wahren J, Foyt H, Daniels M, Arezzo JC. Long-acting C-peptide and neuropathy in type 1 diabetes: A 12-month clinical trial. Diabetes Care  2016; 39(4): 596-602.
[http://dx.doi.org/10.2337/dc15-2068] [PMID: 26884473] 
[15] 
Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol  2002; 50: 393-413.
[http://dx.doi.org/10.1016/S0074-7742(02)50083-0] [PMID: 12198818] 
[16] 
Vinik AI, Bril V, Kempler P, et al. MBBQ Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther  2005; 27(8): 1164-80.
[http://dx.doi.org/10.1016/j.clinthera.2005.08.001] [PMID: 16199243] 
[17] 
Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care  1994; 17(11): 1281-9.
[http://dx.doi.org/10.2337/diacare.17.11.1281] [PMID: 7821168] 
[18] 
Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population 1993.
[19] 
Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol  1980; 8(6): 590-6.
[http://dx.doi.org/10.1002/ana.410080608] [PMID: 7212646] 
[20] 
Bril V, Tomioka S, Buchanan RA, Perkins BA. mTCNS Study Group. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med  2009; 26(3): 240-6.
[http://dx.doi.org/10.1111/j.1464-5491.2009.02667.x] [PMID: 19317818] 
[21] 
Valk GD, de Sonnaville JJJ, van Houtum WH, et al. The assessment of diabetic polyneuropathy in daily clinical practice: reproducibility and validity of Semmes Weinstein monofilaments examination and clinical neurological examination. Muscle Nerve  1997; 20(1): 116-8.
[http://dx.doi.org/10.1002/(SICI)1097-4598(199701)20:1<116:AID-MUS19>3.0.CO;2-2] [PMID: 8995595] 
[22] 
Valk GD, Nauta JJP, Strijers RLM, Bertelsmann FW. Clinical examination versus neurophysiological examination in the diagnosis of diabetic polyneuropathy. Diabet Med  1992; 9(8): 716-21.
[http://dx.doi.org/10.1111/j.1464-5491.1992.tb01879.x] [PMID: 1395463] 
[23] 
Meijer JWG, van Sonderen E, Blaauwwiekel EE, et al. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care  2000; 23(6): 750-3.
[http://dx.doi.org/10.2337/diacare.23.6.750] [PMID: 10840990] 
[24] 
Dyck PJ, Karnes J, O’Brien PC, Swanson CJ. Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology  1986; 36(10): 1300-8.
[http://dx.doi.org/10.1212/WNL.36.10.1300] [PMID: 3762934] 
[25] 
Meijer JWG, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med  2002; 19(11): 962-5.
[http://dx.doi.org/10.1046/j.1464-5491.2002.00819.x] [PMID: 12421436] 
[26] 
Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O’Brien PC. Variables influencing neuropathic endpoints: The rochester diabetic neuropathy study of healthy subjects. Neurology  1995; 45(6): 1115-21.
[http://dx.doi.org/10.1212/WNL.45.6.1115] [PMID: 7783874] 
[27] 
Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol  1999; 41(Suppl. 1): 8-13.
[http://dx.doi.org/10.1159/000052074] [PMID: 10023123] 
[28] 
Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology  1997; 49(1): 229-39.
[http://dx.doi.org/10.1212/WNL.49.1.229] [PMID: 9222195] 
[29] 
Bril V, Perkins BA. Validation of the Toronto clinical scoring system for diabetic polyneuropathy. Diabetes Care  2002; 25(11): 2048-52.
[http://dx.doi.org/10.2337/diacare.25.11.2048] [PMID: 12401755] 
[30] 
Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve  1988; 11(1): 21-32.
[http://dx.doi.org/10.1002/mus.880110106] [PMID: 3277049] 
[31] 
Bastyr EJ III, Price KL, Bril V. MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther  2005; 27(8): 1278-94.
[http://dx.doi.org/10.1016/j.clinthera.2005.08.002] [PMID: 16199253] 
[32] 
Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology  1999; 53(8): 1660-4.
[http://dx.doi.org/10.1212/WNL.53.8.1660] [PMID: 10563609] 
[33] 
Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia  1995; 38(12): 1425-33.
[http://dx.doi.org/10.1007/BF00400603] [PMID: 8786016] 
[34] 
Rolke R, Magerl W, Campbell KA, et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain  2006; 10(1): 77-88.
[http://dx.doi.org/10.1016/j.ejpain.2005.02.003] [PMID: 16291301] 
[35] 
Vollert J, Attal N, Baron R, et al. Quantitative sensory testing using DFNS protocol in Europe: an evaluation of heterogeneity across multiple centers in patients with peripheral neuropathic pain and healthy subjects. Pain  2016; 157(3): 750-8.
[http://dx.doi.org/10.1097/j.pain.0000000000000433] [PMID: 26630440] 
[36] 
Shy ME, Frohman EM, So YT, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Quantitative sensory testing: Report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology  2003; 60(6): 898-904.
[http://dx.doi.org/10.1212/01.WNL.0000058546.16985.11] [PMID: 12654951] 
[37] 
Malik RA. Why are there no good treatments for diabetic neuropathy? Lancet Diabetes Endocrinol  2014; 2(8): 607-9.
[http://dx.doi.org/10.1016/S2213-8587(14)70067-1] [PMID: 24746878] 
[38] 
Vollert J, Maier C, Attal N, et al. Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations. Pain  2017; 158(8): 1446-55.
[http://dx.doi.org/10.1097/j.pain.0000000000000935] [PMID: 28595241] 
[39] 
Dyck PJ, Overland CJ, Low PA, et al. Cl vs. NPhys Trial Investigators. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve  2010; 42(2): 157-64.
[http://dx.doi.org/10.1002/mus.21661] [PMID: 20658599] 
[40] 
Malik RA. Which test for diagnosing early human diabetic neuropathy? Diabetes  2014; 63(7): 2206-8.
[http://dx.doi.org/10.2337/db14-0492] [PMID: 24962918] 
[41] 
Dyck PJ, Norell JE, Tritschler H, et al. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care  2007; 30(10): 2619-25.
[http://dx.doi.org/10.2337/dc06-2479] [PMID: 17513707] 
[42] 
Kong X, Lesser EA, Potts FA, Gozani SN. Utilization of nerve conduction studies for the diagnosis of polyneuropathy in patients with diabetes: a retrospective analysis of a large patient series. J Diabetes Sci Technol  2008; 2(2): 268-74.
[http://dx.doi.org/10.1177/193229680800200217] [PMID: 19885354] 
[43] 
Holland NR, Stocks A, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Intraepidermal nerve fiber density in patients with painful sensory neuropathy. Neurology  1997; 48(3): 708-11.
[http://dx.doi.org/10.1212/WNL.48.3.708] [PMID: 9065552] 
[44] 
Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology  1996; 47(4): 1042-8.
[http://dx.doi.org/10.1212/WNL.47.4.1042] [PMID: 8857742] 
[45] 
Lauria G, Cornblath DR, Johansson O, et al. European Federation of Neurological Societies. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol  2005; 12(10): 747-58.
[http://dx.doi.org/10.1111/j.1468-1331.2005.01260.x] [PMID: 16190912] 
[46] 
Lauria G, Hsieh ST, Johansson O, et al.  European Federation of
Neurological Societies; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society Eur J Neurol  2010; 17(7): 903-12. e44-e49
[http://dx.doi.org/10.1111/j.1468-1331.2010.03023.x] [PMID: 20642627] 
[47] 
Bakkers M, Merkies ISJ, Lauria G, et al. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology  2009; 73(14): 1142-8.
[http://dx.doi.org/10.1212/WNL.0b013e3181bacf05] [PMID: 19805731] 
[48] 
Gøransson LG, Mellgren SI, Lindal S, Omdal R. The effect of age and gender on epidermal nerve fiber density. Neurology  2004; 62(5): 774-7.
[http://dx.doi.org/10.1212/01.WNL.0000113732.41127.8F] [PMID: 15007129] 
[49] 
Lauria G, Bakkers M, Schmitz C, et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst  2010; 15(3): 202-7.
[http://dx.doi.org/10.1111/j.1529-8027.2010.00271.x] [PMID: 21040142] 
[50] 
Smith AG, Howard JR, Kroll R, et al. The reliability of skin biopsy with measurement of intraepidermal nerve fiber density. J Neurol Sci  2005; 228(1): 65-9.
[http://dx.doi.org/10.1016/j.jns.2004.09.032] [PMID: 15607212] 
[51] 
McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol  1998; 55(12): 1513-20.
[http://dx.doi.org/10.1001/archneur.55.12.1513] [PMID: 9865794] 
[52] 
Koskinen M, Hietaharju A, Kyläniemi M, et al. A quantitative method for the assessment of intraepidermal nerve fibers in small-fiber neuropathy. J Neurol  2005; 252(7): 789-94.
[http://dx.doi.org/10.1007/s00415-005-0743-x] [PMID: 15789134] 
[53] 
Wöpking S, Scherens A, Haussleiter IS, et al. Significant difference between three observers in the assessment of intraepidermal nerve fiber density in skin biopsy. BMC Neurol  2009; 9: 13.
[http://dx.doi.org/10.1186/1471-2377-9-13] [PMID: 19335896] 
[54] 
Provitera V, Gibbons CH, Wendelschafer-Crabb G, et al. A multi-center, multinational age- and gender-adjusted normative dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg. Eur J Neurol  2016; 23(2): 333-8.
[http://dx.doi.org/10.1111/ene.12842] [PMID: 26493160] 
[55] 
Nolano M, Biasiotta A, Lombardi R, et al. Epidermal innervation morphometry by immunofluorescence and bright-field microscopy. J Peripher Nerv Syst  2015; 20(4): 387-91.
[http://dx.doi.org/10.1111/jns.12146] [PMID: 26309146] 
[56] 
Lauria G, Dacci P, Lombardi R, et al. Side and time variability of intraepidermal nerve fiber density. Neurology  2015; 84(23): 2368-71.
[http://dx.doi.org/10.1212/WNL.0000000000001666] [PMID: 25972491] 
[57] 
Karlsson P, Porretta-Serapiglia C, Lombardi R, Jensen TS, Lauria G. Dermal innervation in healthy subjects and small fiber neuropathy patients: a stereological reappraisal. J Peripher Nerv Syst  2013; 18(1): 48-53.
[http://dx.doi.org/10.1111/jns5.12007] [PMID: 23521644] 
[58] 
Karlsson P, Møller AT, Jensen TS, Nyengaard JR. Epidermal nerve fiber length density estimation using global spatial sampling in healthy subjects and neuropathy patients. J Neuropathol Exp Neurol  2013; 72(3): 186-93.
[http://dx.doi.org/10.1097/NEN.0b013e318284e849] [PMID: 23399897] 
[59] 
Rosenberg ME, Tervo TM, Immonen IJ, Müller LJ, Grönhagen-Riska C, Vesaluoma MH. Corneal structure and sensitivity in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci  2000; 41(10): 2915-21.
[http://dx.doi.org/10.1016/S0304-5412(12)70418-3] [PMID: 10967045] 
[60] 
Malik RA, Kallinikos P, Abbott CA, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia  2003; 46(5): 683-8.
[http://dx.doi.org/10.1007/s00125-003-1086-8] [PMID: 12739016] 
[61] 
Hertz P, Bril V, Orszag A, et al. Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy. Diabet Med  2011; 28(10): 1253-60.
[http://dx.doi.org/10.1111/j.1464-5491.2011.03299.x] [PMID: 21434993] 
[62] 
Pacaud D, Romanchuk KG, Tavakoli M, et al. The reliability and reproducibility of corneal confocal microscopy in children. Invest Ophthalmol Vis Sci  2015; 56(9): 5636-40.
[http://dx.doi.org/10.1167/iovs.15-16995] [PMID: 26313299] 
[63] 
Petropoulos IN, Manzoor T, Morgan P, et al. Repeatability of in vivo corneal confocal microscopy to quantify corneal nerve morphology. Cornea  2013; 32(5): e83-9.
[http://dx.doi.org/10.1097/ICO.0b013e3182749419] [PMID: 23172119] 
[64] 
Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care  2007; 30(10): 2608-12.
[http://dx.doi.org/10.2337/dc07-0870] [PMID: 17623821] 
[65] 
Azmi S, Jeziorska M, Ferdousi M, Petropoulos IN, Ponirakis G, Marshall A, et al. Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation Diabetolgia  2019; 62(8): 1478-87.
[66] 
Perkins BA, Lovblom LE, Bril V, et al. Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia  2018; 61(8): 1856-61.
[http://dx.doi.org/10.1007/s00125-018-4653-8] [PMID: 29869146] 
[67] 
Guthoff RF, Zhivov A, Stachs O. In vivo confocal microscopy, an inner vision of the cornea - a major review. Clin Exp Ophthalmol  2009; 37(1): 100-17.
[http://dx.doi.org/10.1111/j.1442-9071.2009.02016.x] [PMID: 19338608] 
[68] 
Chen X, Graham J, Dabbah MA, et al. Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes Care  2015; 38(6): 1138-44.
[http://dx.doi.org/10.2337/dc14-2422] [PMID: 25795415] 
[69] 
Alam U, Jeziorska M, Petropoulos IN, et al. Diagnostic utility of corneal confocal microscopy and intra-epidermal nerve fibre density in diabetic neuropathy. PLoS One  2017; 12(7)e0180175
[http://dx.doi.org/10.1371/journal.pone.0180175] [PMID: 28719619] 
[70] 
Kalteniece A, Ferdousi M, Azmi S, et al. Corneal confocal microscopy detects small nerve fibre damage in patients with painful diabetic neuropathy. Sci Rep  2020; 10(1): 3371.
[http://dx.doi.org/10.1038/s41598-020-60422-7] [PMID: 32099076] 
[71] 
Andersen ST, Grosen K, Tankisi H, et al. Corneal confocal microscopy as a tool for detecting diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes: ADDITION-Denmark. J Diabetes Complications  2018; 32(12): 1153-9.
[http://dx.doi.org/10.1016/j.jdiacomp.2018.09.016] [PMID: 30309785] 
[72] 
Tavakoli M, Hossain P, Malik RA. Clinical applications of corneal confocal microscopy. Clin Ophthalmol  2008; 2(2): 435-45.
[http://dx.doi.org/10.2147/opth.s1490] [PMID: 19668734] 
[73] 
Tavakoli M, Ferdousi M, Petropoulos IN, et al. Normative values for corneal nerve morphology assessed using corneal confocal microscopy: a multinational normative data set. Diabetes Care  2015; 38(5): 838-43.
[http://dx.doi.org/10.2337/dc14-2311] [PMID: 25633665] 
[74] 
Benarroch EE, Low PA. The acetylcholine-induced flare response in evaluation of small fiber dysfunction. Ann Neurol  1991; 29(6): 590-5.
[http://dx.doi.org/10.1002/ana.410290604] [PMID: 1892361] 
[75] 
Stevens MJ, Edmonds ME, Douglas SL, Watkins PJ. Influence of neuropathy on the microvascular response to local heating in the human diabetic foot. Clin Sci (Lond)  1991; 80(3): 249-56.
[http://dx.doi.org/10.1042/cs0800249] [PMID: 1850685] 
[76] 
Yajnik CS, Kantikar VV, Pande AJ, Deslypere JP. Quick and simple evaluation of sudomotor function for screening of diabetic neuropathy. ISRN Endocrinol 2012.2012103714
[http://dx.doi.org/10.5402/2012/103714] [PMID: 22830040] 
[77] 
Mayaudon H, Miloche PO, Bauduceau B. A new simple method for assessing sudomotor function: relevance in type 2 diabetes. Diabetes Metab  2010; 36(6 Pt 1): 450-4.
[http://dx.doi.org/10.1016/j.diabet.2010.05.004] [PMID: 20739207] 
[78] 
Papanas N, Papatheodorou K, Christakidis D, et al. Evaluation of a new indicator test for sudomotor function (Neuropad) in the diagnosis of peripheral neuropathy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes  2005; 113(4): 195-8.
[http://dx.doi.org/10.1055/s-2005-837735] [PMID: 15891953] 
[79] 
Papanas N, Papatheodorou K, Papazoglou D, Kotsiou S, Maltezos E. A prospective study on the use of the indicator test Neuropad® for the early diagnosis of peripheral neuropathy in type 2 diabetes. Exp Clin Endocrinol Diabetes  2011; 119(2): 122-5.
[http://dx.doi.org/10.1055/s-0030-1261934] [PMID: 20690070] 
[80] 
Sharma S, Vas PR, Rayman G. Assessment of diabetic neuropathy using a point-of-care nerve conduction device shows significant associations with the LDIFLARE method and clinical neuropathy scoring. J Diabetes Sci Technol  2015; 9(1): 123-31.
[http://dx.doi.org/10.1177/1932296814551044] [PMID: 25231114] 
[81] 
Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve  1998; 21(2): 137-58.
[http://dx.doi.org/10.1002/(SICI)1097-4598(199802)21:2<137:AID-MUS1>3.0.CO;2-C] [PMID: 9466589] 
[82] 
Hennings K, Frahm KS, Petrini L, Andersen OK, Arendt-Nielsen L, Mørch CD. Membrane properties in small cutaneous nerve fibers in humans. Muscle Nerve  2017; 55(2): 195-201.
[http://dx.doi.org/10.1002/mus.25234] [PMID: 27366884] 
[83] 
Potenzieri C, Undem BJ. Basic mechanisms of itch. Clin Exp Allergy  2012; 42(1): 8-19.
[http://dx.doi.org/10.1111/j.1365-2222.2011.03791.x] [PMID: 21645138] 
[84] 
Schmelz M. Itch Processing in the Skin. Front Med (Lausanne)  2019; 6: 167-7.
[http://dx.doi.org/10.3389/fmed.2019.00167] [PMID: 31380380] 
[85] 
Group TDC. The effect of intensive treatment of diabetes on the
development and progression of long term complications in insulin
dependent diabetes mellitus N Engl J Med  1993; 329: 977-86.
[http://dx.doi.org/10.1056/NEJM199309303291401] [PMID: 8366922] 
[86] 
Martin CL, Albers JW, Pop-Busui R. DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care  2014; 37(1): 31-8.
[http://dx.doi.org/10.2337/dc13-2114] [PMID: 24356595] 
[87] 
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract  1995; 28(2): 103-17.
[http://dx.doi.org/10.1016/0168-8227(95)01064-K] [PMID: 7587918] 
[88] 
Turner R. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet  1998; 352(9131): 837-53.
[http://dx.doi.org/10.1016/S0140-6736(98)07019-6] [PMID: 9742976] 
[89] 
Ismail-Beigi F, Craven T, Banerji MA, et al. ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet  2010; 376(9739): 419-30.
[http://dx.doi.org/10.1016/S0140-6736(10)60576-4] [PMID: 20594588] 
[90] 
Charles M, Ejskjaer N, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care  2011; 34(10): 2244-9.
[http://dx.doi.org/10.2337/dc11-0903] [PMID: 21816977] 
[91] 
Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med  2003; 348(5): 383-93.
[http://dx.doi.org/10.1056/NEJMoa021778] [PMID: 12556541] 
[92] 
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med  2009; 360(2): 129-39.
[http://dx.doi.org/10.1056/NEJMoa0808431] [PMID: 19092145] 
[93] 
Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet  1998; 352(9145): 1978-81.
[http://dx.doi.org/10.1016/S0140-6736(98)02478-7] [PMID: 9872248] 
[94] 
Didangelos T, Tziomalos K, Margaritidis C, et al. Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for Two Years on Autonomic and Peripheral Neuropathy in Patients with Diabetes Mellitus. J Diabetes Res 2017.20176719239
[http://dx.doi.org/10.1155/2017/6719239] [PMID: 28373993] 
[95] 
Ruggenenti P, Lauria G, Iliev IP, et al. DEMAND Study Investigators. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension  2011; 58(5): 776-83.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.174474] [PMID: 21931073] 
[96] 
Davis TME, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia  2008; 51(4): 562-6.
[http://dx.doi.org/10.1007/s00125-007-0919-2] [PMID: 18193189] 
[97] 
Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol  2014; 2(11): 894-900.
[http://dx.doi.org/10.1016/S2213-8587(14)70173-1] [PMID: 25217178] 
[98] 
Gaist D, Jeppesen U, Andersen M, García Rodríguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology  2002; 58(9): 1333-7.
[http://dx.doi.org/10.1212/WNL.58.9.1333] [PMID: 12011277] 
[99] 
Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med  1987; 147(8): 1442-4.
[http://dx.doi.org/10.1001/archinte.1987.00370080078016] [PMID: 3115210] 
[100] 
Spallone V. Management of painful diabetic neuropathy: guideline guidance or jungle? Curr Diab Rep  2012; 12(4): 403-13.
[http://dx.doi.org/10.1007/s11892-012-0287-2] [PMID: 22623150] 
[101] 
Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis  2015; 6(1): 15-28.
[http://dx.doi.org/10.1177/2040622314552071] [PMID: 25553239] 
[102] 
Selvarajah D, Petrie J, White D, et al. OPTION-DM group. Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial. Trials  2018; 19(1): 578.
[http://dx.doi.org/10.1186/s13063-018-2959-y] [PMID: 30348206] 
[103] 
Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain  2013; 154(12): 2616-25.
[http://dx.doi.org/10.1016/j.pain.2013.05.043] [PMID: 23732189] 
[104] 
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev  2007; CD005454(4)CD005454
[http://dx.doi.org/10.1002/14651858.CD005454.pub2] [PMID: 17943857] 
[105] 
Boyle J, Eriksson MEV, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care  2012; 35(12): 2451-8.
[http://dx.doi.org/10.2337/dc12-0656] [PMID: 22991449] 
[106] 
Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician  2013; 16(6): E705-14.
[PMID: 24284851] 
[107] 
Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med  2014; 161(9): 639-49.
[http://dx.doi.org/10.7326/M14-0511] [PMID: 25364885] 
[108] 
Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology  2006; 67(8): 1411-20.
[http://dx.doi.org/10.1212/01.wnl.0000240225.04000.1a] [PMID: 17060567] 
[109] 
Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med  2005; 6(5): 346-56.
[http://dx.doi.org/10.1111/j.1526-4637.2005.00061.x] [PMID: 16266355] 
[110] 
Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain  2005; 116(1-2): 109-18.
[http://dx.doi.org/10.1016/j.pain.2005.03.029] [PMID: 15927394] 
[111] 
Gao Y, Ning G, Jia WP, et al. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J (Engl)  2010; 123(22): 3184-92.
[http://dx.doi.org/10.3760/cma.j.issn.0366-6999.2010.22.003] [PMID: 21163113] 
[112] 
Yasuda H, Hotta N, Nakao K, Kasuga M, Kashiwagi A, Kawamori R. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan. J Diabetes Investig  2011; 2(2): 132-9.
[http://dx.doi.org/10.1111/j.2040-1124.2010.00073.x] [PMID: 24843472] 
[113] 
Gao Y, Guo X, Han P, et al. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo. Int J Clin Pract  2015; 69(9): 957-66.
[http://dx.doi.org/10.1111/ijcp.12641] [PMID: 25939897] 
[114] 
Rowbotham MC, Arslanian A, Nothaft W, et al. Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain. Pain  2012; 153(4): 862-8.
[http://dx.doi.org/10.1016/j.pain.2012.01.009] [PMID: 22386472] 
[115] 
Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology  2017; 88(20): 1958-67.
[http://dx.doi.org/10.1212/WNL.0000000000003882] [PMID: 28341643] 
[116] 
Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev  2014; 2014(1)CD007115
[http://dx.doi.org/10.1002/14651858.CD007115.pub3] [PMID: 24385423] 
[117] 
Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev  2015; 2017(8)CD011091
[http://dx.doi.org/10.1002/14651858.CD011091.pub2] [PMID: 26298465] 
[118] 
Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain  2004; 110(3): 697-706.
[http://dx.doi.org/10.1016/j.pain.2004.05.010] [PMID: 15288411] 
[119] 
Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand  2006; 114(3): 177-80.
[http://dx.doi.org/10.1111/j.1600-0404.2005.00559.x] [PMID: 16911345] 
[120] 
Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand  2006; 113(6): 395-404.
[http://dx.doi.org/10.1111/j.1600-0404.2006.00631.x] [PMID: 16674606] 
[121] 
Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain  2005; 9(5): 543-54.
[http://dx.doi.org/10.1016/j.ejpain.2004.11.006] [PMID: 16139183] 
[122] 
Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev 2017.12CD007963
[http://dx.doi.org/10.1002/14651858.CD007963.pub3] [PMID: 29199767] 
[123] 
Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain  2014; 155(11): 2263-73.
[http://dx.doi.org/10.1016/j.pain.2014.08.014] [PMID: 25139589] 
[124] 
Thienel U, Neto W, Schwabe SK, Vijapurkar U. Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand  2004; 110(4): 221-31.
[http://dx.doi.org/10.1111/j.1600-0404.2004.00338.x] [PMID: 15355485] 
[125] 
Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain  2007; 128(1-2): 169-79.
[http://dx.doi.org/10.1016/j.pain.2006.09.040] [PMID: 17161535] 
[126] 
E. Brookes M. Eldabe S. Batterham A. Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials. Curr Neuropharmacol  2016; 15: 217-31.
[http://dx.doi.org/10.2174/1570159x14666160210142056] 
[127] 
Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain  2004; 110(3): 628-38.
[http://dx.doi.org/10.1016/j.pain.2004.05.001] [PMID: 15288403] 
[128] 
Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology  2004; 63(11): 2104-10.
[http://dx.doi.org/10.1212/01.WNL.0000145767.36287.A1] [PMID: 15596757] 
[129] 
Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain  2005; 6(4): 253-60.
[http://dx.doi.org/10.1016/j.jpain.2004.12.007] [PMID: 15820913] 
[130] 
Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain  2005; 115(3): 254-63.
[http://dx.doi.org/10.1016/j.pain.2005.02.032] [PMID: 15911152] 
[131] 
Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain  2008; 12(2): 203-13.
[http://dx.doi.org/10.1016/j.ejpain.2007.05.003] [PMID: 17631400] 
[132] 
Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol  2008; 8: 33.
[http://dx.doi.org/10.1186/1471-2377-8-33] [PMID: 18796160] 
[133] 
Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med  2011; 28(1): 109-16.
[http://dx.doi.org/10.1111/j.1464-5491.2010.03152.x] [PMID: 21166852] 
[134] 
Jiang W, Ladd S, Martsberger C, et al. Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy. J Clin Psychopharmacol  2011; 31(2): 207-13.
[http://dx.doi.org/10.1097/JCP.0b013e31820f4f57] [PMID: 21346609] 
[135] 
Raskin P, Huffman C, Toth C, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain  2014; 30(5): 379-90.
[http://dx.doi.org/10.1097/AJP.0b013e31829ea1a1] [PMID: 23887339] 
[136] 
Rauck R, Makumi CW, Schwartz S, et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract  2013; 13(6): 485-96.
[http://dx.doi.org/10.1111/papr.12014] [PMID: 23186035] 
[137] 
Zhang SS, Wu Z, Zhang LC, et al. Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta-analysis. Acta Anaesthesiol Scand  2015; 59(2): 147-59.
[http://dx.doi.org/10.1111/aas.12420] [PMID: 25328117] 
[138] 
Mu Y, Liu X, Li Q, et al. Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: A randomized placebo-controlled trial. J Diabetes  2018; 10(3): 256-65.
[http://dx.doi.org/10.1111/1753-0407.12585] [PMID: 28727270] 
[139] 
Huffman C, Stacey BR, Tuchman M, et al. Efficacy and safety of pregabalin in the treatment of patients with painful diabetic peripheral neuropathy and pain on walking. Clin J Pain  2015; 31(11): 946-58.
[http://dx.doi.org/10.1097/AJP.0000000000000198] [PMID: 25565583] 
[140] 
Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA  1998; 280(21): 1831-6.
[http://dx.doi.org/10.1001/jama.280.21.1831] [PMID: 9846777] 
[141] 
Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry  1999; 66(2): 251-2.
[http://dx.doi.org/10.1136/jnnp.66.2.251] [PMID: 10071116] 
[142] 
Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis  2001; 3(2): 53-62.
[http://dx.doi.org/10.1097/00131402-200112000-00002] [PMID: 19078655] 
[143] 
Pérez HET, Sánchez GF. Gabapentin therapy for diabetic neuropathic pain. Am J Med  2000; 108(8): 689.
[http://dx.doi.org/10.1016/S0002-9343(00)00398-3] [PMID: 10896633] 
[144] 
Sandercock D, Cramer M, Wu J, Chiang YK, Biton V, Heritier M. Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Care  2009; 32(2): e20-0.
[http://dx.doi.org/10.2337/dc08-1450] [PMID: 19171730] 
[145] 
Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017.6CD007938
[http://dx.doi.org/10.1002/14651858.CD007938.pub4] [PMID: 28597471] 
[146] 
Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med  1999; 159(16): 1931-7.
[http://dx.doi.org/10.1001/archinte.159.16.1931] [PMID: 10493324] 
[147] 
Sang CN, Booher S, Gilron I, Parada S, Max MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology  2002; 96(5): 1053-61.
[http://dx.doi.org/10.1097/00000542-200205000-00005] [PMID: 11981142] 
[148] 
Shaibani AI, Pope LE, Thisted R, Hepner A. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. Pain Med  2012; 13(2): 243-54.
[http://dx.doi.org/10.1111/j.1526-4637.2011.01316.x] [PMID: 22314263] 
[149] 
Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician  2008; 11(2): S105-20.
[http://dx.doi.org/10.1007/978-3-540-35423-9_14] [PMID: 18443635] 
[150] 
Gaskell H, Derry S, Stannard C, Moore RA. Oxycodone for neuropathic pain in adults. Cochrane Database Syst Rev 2016.7CD010692
[http://dx.doi.org/10.1002/14651858.CD010692.pub3] [PMID: 27465317] 
[151] 
Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology  1998; 50(6): 1842-6.
[http://dx.doi.org/10.1212/WNL.50.6.1842] [PMID: 9633738] 
[152] 
Harati Y, Gooch C, Swenson M, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications  2000; 14(2): 65-70.
[http://dx.doi.org/10.1016/S1056-8727(00)00060-X] [PMID: 10959067] 
[153] 
Sindrup SH, Konder R, Lehmann R, et al. Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy. Eur J Pain  2012; 16(6): 849-59.
[http://dx.doi.org/10.1002/j.1532-2149.2011.00069.x] [PMID: 22337471] 
[154] 
Sindrup SH, Andersen G, Madsen C, Smith T, Brøsen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain  1999; 83(1): 85-90.
[http://dx.doi.org/10.1016/S0304-3959(99)00079-2] [PMID: 10506675] 
[155] 
Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin  2011; 27(1): 151-62.
[http://dx.doi.org/10.1185/03007995.2010.537589] [PMID: 21162697] 
[156] 
Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol  2011; 7(10): 573-83.
[http://dx.doi.org/10.1038/nrneurol.2011.137] [PMID: 21912405] 
[157] 
Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol  2012; 167(4): 465-71.
[http://dx.doi.org/10.1530/EJE-12-0555] [PMID: 22837391] 
[158] 
Ziegler D, Ametov A, Barinov A, et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care  2006; 29(11): 2365-70.
[http://dx.doi.org/10.2337/dc06-1216] [PMID: 17065669] 
[159] 
Brownlee M. The pathobiology of diabetic complications: A unifying mechanism Diabetes.  American Diabetes Association 2005; Vol. 54: pp. 1615-25.
[160] 
Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol  2002; 50: 325-92.
[http://dx.doi.org/10.1016/S0074-7742(02)50082-9] [PMID: 12198816] 
[161] 
Boulton AJM, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev  2013; 29(5): 327-33.
[http://dx.doi.org/10.1002/dmrr.2397] [PMID: 23381942] 
[162] 
Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev 2007; (4): CD004572
[http://dx.doi.org/10.1002/14651858.CD004572.pub2] [PMID: 17943821] 
[163] 
Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care  2006; 29(7): 1538-44.
[http://dx.doi.org/10.2337/dc05-2370] [PMID: 16801576] 
[164] 
Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol  2014; 18(1): 1-14.
[http://dx.doi.org/10.4196/kjpp.2014.18.1.1] [PMID: 24634591] 
[165] 
Haupt E, Ledermann H, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther  2005; 43(2): 71-7.
[http://dx.doi.org/10.5414/CPP43071] [PMID: 15726875] 
[166] 
Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes  2008; 116(10): 600-5.
[http://dx.doi.org/10.1055/s-2008-1065351] [PMID: 18473286] 
[167] 
Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes  1996; 104(4): 311-6.
[http://dx.doi.org/10.1055/s-0029-1211460] [PMID: 8886748] 
[168] 
Fraser DA, Diep LM, Hovden IA, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care  2012; 35(5): 1095-7.
[http://dx.doi.org/10.2337/dc11-1895] [PMID: 22446172] 
[169] 
Kamiya H, Zhang W, Sima AAF. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol  2004; 56(6): 827-35.
[http://dx.doi.org/10.1002/ana.20295] [PMID: 15497155] 
[170] 
Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindström P, Wahren J. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes  2003; 52(2): 536-41.
[http://dx.doi.org/10.2337/diabetes.52.2.536] [PMID: 12540632] 
[171] 
Ekberg K, Brismar T, Johansson BL, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care  2007; 30(1): 71-6.
[http://dx.doi.org/10.2337/dc06-1274] [PMID: 17192336] 
[172] 
Musharraf MU, Ahmad Z, Yaqub Z. Comparison of topical capsaicin and topical turpentine Oil for treatment of painful diabetic neuropathy. J Ayub Med Coll Abbottabad  2017; 29(3): 384-7.
[PMID: 29076666] 
[173] 
The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med  1991; 151(11): 2225-9.
[http://dx.doi.org/10.1001/archinte.1991.00400110079017] [PMID: 1953227] 
[174] 
Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care  1992; 15(1): 8-14.
[http://dx.doi.org/10.2337/diacare.15.1.8] [PMID: 1737545] 
[175] 
Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study. J Pain  2017; 18(1): 42-53.
[http://dx.doi.org/10.1016/j.jpain.2016.09.008] [PMID: 27746370] 
[176] 
McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol  2000; 49(6): 574-9.
[http://dx.doi.org/10.1046/j.1365-2125.2000.00200.x] [PMID: 10848721] 
[177] 
Wrzosek A, Woron J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J. Topical clonidine for neuropathic pain. Cochrane Database Syst Rev 2015.8CD010967
[http://dx.doi.org/10.1002/14651858.CD010967.pub2] [PMID: 26329307] 
[178] 
Yuen KCJ, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care  2002; 25(10): 1699-703.
[http://dx.doi.org/10.2337/diacare.25.10.1699] [PMID: 12351464] 
[179] 
Catterall WA. Molecular mechanisms of gating and drug block of sodium channels. Novartis Found Symp  2002; 241: 206-18.
[http://dx.doi.org/10.1002/0470846682.ch14] [PMID: 11771647] 
[180] 
Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin  2009; 25(7): 1663-76.
[http://dx.doi.org/10.1185/03007990903047880] [PMID: 19485723] 
[181] 
Kastrup J, Petersen P, Dejgård A, Angelo HR, Hilsted J. Intravenous lidocaine infusion--a new treatment of chronic painful diabetic neuropathy? Pain  1987; 28(1): 69-75.
[http://dx.doi.org/10.1016/0304-3959(87)91061-X] [PMID: 3822496] 
[182] 
Viola V, Newnham HH, Simpson RW. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complications  2006; 20(1): 34-9.
[http://dx.doi.org/10.1016/j.jdiacomp.2005.05.007] [PMID: 16389165] 
[183] 
Wright JM, Oki JC, Graves L III. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother  1997; 31(1): 29-34.
[http://dx.doi.org/10.1177/106002809703100103] [PMID: 8997461] 
[184] 
Oskarsson P, Ljunggren JG, Lins PE. The Mexiletine Study Group. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care  1997; 20(10): 1594-7.
[http://dx.doi.org/10.2337/diacare.20.10.1594] [PMID: 9314641] 
[185] 
Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care  1992; 15(11): 1550-5.
[http://dx.doi.org/10.2337/diacare.15.11.1550] [PMID: 1468285] 
[186] 
Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet  1988; 1(8575-6): 9-11.
[http://dx.doi.org/10.1016/S0140-6736(88)90999-3] [PMID: 2891940] 
[187] 
Ghasemi M, Ansari M, Basiri K, Shaigannejad V. The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy. J Res Med Sci  2014; 19(2): 106-11.
[PMID: 24778662] 
[188] 
Chen WT, Yuan RY, Chiang SC, et al. OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain  2013; 29(4): 305-10.
[http://dx.doi.org/10.1097/AJP.0b013e318255c132] [PMID: 23462284] 
[189] 
Bril V, England J, Franklin GM, et al. American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology  2011; 76(20): 1758-65.
[http://dx.doi.org/10.1212/WNL.0b013e3182166ebe] [PMID: 21482920] 
[190] 
Thakral G, Kim PJ, LaFontaine J, Menzies R, Najafi B, Lavery LA. Electrical stimulation as an adjunctive treatment of painful and sensory diabetic neuropathy. J Diabetes Sci Technol  2013; 7: 1202-9.
[191] 
Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care  2014; 37(11): 3016-24.
[http://dx.doi.org/10.2337/dc14-0684] [PMID: 25216508] 
[192] 
de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain  2014; 155(11): 2426-31.
[http://dx.doi.org/10.1016/j.pain.2014.08.031] [PMID: 25180016] 
[193] 
van Beek M, Slangen R, Schaper NC, et al. Sustained treatment effect of spinal cord stimulation in painful diabetic peripheral Neuropathy: 24-Month Follow-up of a prospective Two-Center randomized controlled trial. Diabetes Care  2015; 38(9): e132-4.
[http://dx.doi.org/10.2337/dc15-0740] [PMID: 26116722] 
[194] 
Mekhail NA, Argoff CE, Taylor RS, et al. High-frequency spinal cord stimulation at 10 kHz for the treatment of painful diabetic neuropathy: design of a multicenter, randomized controlled trial (SENZA-PDN). Trials  2020; 21(1): 87.
[http://dx.doi.org/10.1186/s13063-019-4007-y] [PMID: 31941531] 
[195] 
Chen W, Yang GY, Liu B, Manheimer E, Liu JP. Manual acupuncture for treatment of diabetic peripheral neuropathy: a systematic review of randomized controlled trials. PLoS One  2013; 8(9)e73764
[http://dx.doi.org/10.1371/journal.pone.0073764] [PMID: 24069229] 
[196] 
Rice ASC, Dworkin RH, McCarthy TD, et al. EMA401-003 study group. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet  2014; 383(9929): 1637-47.
[http://dx.doi.org/10.1016/S0140-6736(13)62337-5] [PMID: 24507377] 
[197] 
Zakrzewska JM, Palmer J, Morisset V, et al. study investigators. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol  2017; 16(4): 291-300.
[http://dx.doi.org/10.1016/S1474-4422(17)30005-4] [PMID: 28216232] 
[198] 
Price N, Namdari R, Neville J, et al. Safety and Efficacy of a Topical Sodium Channel Inhibitor (TV-45070) in Patients With Postherpetic Neuralgia (PHN): A Randomized, Controlled, Proof-of-Concept, Crossover Study, With a Subgroup Analysis of the Nav1.7 R1150W Genotype. Clin J Pain  2017; 33(4): 310-8.
[http://dx.doi.org/10.1097/AJP.0000000000000408] [PMID: 28266963] 
Rights & Permissions Print Cite
Article Metrics
112
3
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1574886315666200731173113	Print ISSN 1574-8863
Publisher Name Bentham Science Publisher	Online ISSN 2212-3911
Current Drug Safety

Diabetic Peripheral Neuropathy: Diagnosis and Treatment

Abstract

Related Journals

Related Books

Related Articles
